384 related articles for article (PubMed ID: 22531234)
61. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
Hashmi NA; Cosgrove JF; MacMahon P
Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
[TBL] [Abstract][Full Text] [Related]
62. Cost-effectiveness analysis of palivizumab as respiratory syncytial virus prophylaxis in preterm infants in Sweden.
Neovius K; Buesch K; Sandström K; Neovius M
Acta Paediatr; 2011 Oct; 100(10):1306-14. PubMed ID: 21477089
[TBL] [Abstract][Full Text] [Related]
63. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation.
Law BJ; Langley JM; Allen U; Paes B; Lee DS; Mitchell I; Sampalis J; Walti H; Robinson J; O'Brien K; Majaesic C; Caouette G; Frenette L; Le Saux N; Simmons B; Moisiuk S; Sankaran K; Ojah C; Singh AJ; Lebel MH; Bacheyie GS; Onyett H; Michaliszyn A; Manzi P; Parison D
Pediatr Infect Dis J; 2004 Sep; 23(9):806-14. PubMed ID: 15361717
[TBL] [Abstract][Full Text] [Related]
64. Diminished lung function, RSV infection, and respiratory morbidity in prematurely born infants.
Broughton S; Bhat R; Roberts A; Zuckerman M; Rafferty G; Greenough A
Arch Dis Child; 2006 Jan; 91(1):26-30. PubMed ID: 16188957
[TBL] [Abstract][Full Text] [Related]
65. Impact of immunoprophylaxis with palivizumab on respiratory syncytial virus infection in preterm infants less than 35 weeks in Colombian hospitals.
Galvis C; Colmenares A; Cabrales L; Ibatá L; Marulanda J; Ovalle O; Puello D; Rojas C; Africano M; Ballesteros A; Posso H
Pediatr Pulmonol; 2022 Oct; 57(10):2420-2427. PubMed ID: 35791790
[TBL] [Abstract][Full Text] [Related]
66. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
Resch B; Egger B; Kurath-Koller S; Urlesberger B
Int J Infect Dis; 2017 Apr; 57():50-53. PubMed ID: 28163166
[TBL] [Abstract][Full Text] [Related]
67. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.
Cetinkaya M; Oral TK; Karatekin S; Cebeci B; Babayigit A; Yesil Y
Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1629-1634. PubMed ID: 28391538
[TBL] [Abstract][Full Text] [Related]
68. Rehospitalisations for respiratory disease and respiratory syncytial virus infection in preterm infants of 29-36 weeks gestational age.
Resch B; Pasnocht A; Gusenleitner W; Müller W
J Infect; 2005 Jun; 50(5):397-403. PubMed ID: 15907547
[TBL] [Abstract][Full Text] [Related]
69. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
Lanctôt KL; Masoud ST; Paes BA; Tarride JE; Chiu A; Hui C; Francis PL; Oh PI
Curr Med Res Opin; 2008 Nov; 24(11):3223-37. PubMed ID: 18928643
[TBL] [Abstract][Full Text] [Related]
70. Prophylaxis for respiratory syncytial virus with respiratory syncytial virus-immunoglobulin intravenous among preterm infants of thirty-two weeks gestation and less: reduction in incidence, severity of illness and cost.
Atkins JT; Karimi P; Morris BH; McDavid G; Shim S
Pediatr Infect Dis J; 2000 Feb; 19(2):138-43. PubMed ID: 10694001
[TBL] [Abstract][Full Text] [Related]
71. A novel six consecutive monthly doses of palivizumab prophylaxis protocol for the prevention of respiratory syncytial virus infection in high-risk preterm infants in Taiwan.
Chi H; Hsu CH; Chang JH; Chiu NC; Hung HY; Kao HA; Weng LC; Huang FY; Chiu YY; Chang LY; Huang LM
PLoS One; 2014; 9(6):e100981. PubMed ID: 24971565
[TBL] [Abstract][Full Text] [Related]
72. SENTINEL1: Two-Season Study of Respiratory Syncytial Virus Hospitalizations among U.S. Infants Born at 29 to 35 Weeks' Gestational Age Not Receiving Immunoprophylaxis.
Anderson EJ; DeVincenzo JP; Simões EAF; Krilov LR; Forbes ML; Pannaraj PS; Espinosa CM; Welliver RC; Wolkoff LI; Yogev R; Checchia PA; Domachowske JB; Halasa N; McBride SJ; Kumar VR; McLaurin KK; Rizzo CP; Ambrose CS
Am J Perinatol; 2020 Mar; 37(4):421-429. PubMed ID: 30991438
[TBL] [Abstract][Full Text] [Related]
73. Risk Factors for Respiratory Syncytial Virus Infections in Moderate/Late Premature Infants in Turkey: A Prospective Multicenter Epidemiological Study.
Ozkan H; Celebi S; Koksal N; Hacımustafaoğlu M; Koc E; Tezer H; Cetinkaya M; Cebeci B; Erdeve O; Ozdemir H;
Am J Perinatol; 2021 Dec; 38(14):1540-1546. PubMed ID: 32659789
[TBL] [Abstract][Full Text] [Related]
74. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation.
Sampalis JS; Langley J; Carbonell-Estrany X; Paes B; O'Brien K; Allen U; Mitchell I; Aloy JF; Pedraz C; Michaliszyn AF
Med Decis Making; 2008; 28(4):471-80. PubMed ID: 18556643
[TBL] [Abstract][Full Text] [Related]
75. Prevention of respiratory syncytial viral infections in late preterm infants.
Sankaran K; Kalappurackal M; Tan B
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Apr; 15(4):241-8. PubMed ID: 23607943
[TBL] [Abstract][Full Text] [Related]
76. Restricted Palivizumab Recommendations and the Impact on RSV Hospitalizations among Infants Born at > 29 Weeks of Gestational Age: An Italian Multicenter Study.
Priante E; Tavella E; Girardi E; Militello MA; Mardegan V; Maule MM; Dall'Agnola A; Baraldi E; Manzoni P
Am J Perinatol; 2019 Jul; 36(S 02):S77-S82. PubMed ID: 31238365
[TBL] [Abstract][Full Text] [Related]
77. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.
Blanken MO; Rovers MM; Molenaar JM; Winkler-Seinstra PL; Meijer A; Kimpen JL; Bont L;
N Engl J Med; 2013 May; 368(19):1791-9. PubMed ID: 23656644
[TBL] [Abstract][Full Text] [Related]
78. Hospitalization for lower respiratory tract disease in preterm infants: effects of prophylaxis with palivizumab.
Faldella G; Alessandroni R; Aquilano G; Vandini S; Lanari M; Silvestri M; Pistorio A; Rossi GA
J Chemother; 2010 Feb; 22(1):30-5. PubMed ID: 20227990
[TBL] [Abstract][Full Text] [Related]
79. Results of clinical surveillance during the Japanese first palivizumab season in 2002-2003.
Kusuda S; Koizumi T; Sakai T; Fujimura M; Nishida H; Togari H
Pediatr Int; 2006 Aug; 48(4):362-8. PubMed ID: 16911080
[TBL] [Abstract][Full Text] [Related]
80. Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.
Forbes ML; Kumar VR; Yogev R; Wu X; Robbie GJ; Ambrose CS
Hum Vaccin Immunother; 2014; 10(10):2789-94. PubMed ID: 25483663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
